Department of Clinical Laboratory, Mianyang Central Hospital, Mianyang, PR China.
Department of Clinical Laboratory, Mianyang Central Hospital, Mianyang, PR China.
J Trace Elem Med Biol. 2020 Dec;62:126629. doi: 10.1016/j.jtemb.2020.126629. Epub 2020 Jul 22.
More and more studies have investigated the relationship between serum copper (Cu) and/or zinc (Zn) levels and breast cancer (BC). However, the results are inconsistent. It is unclear whether the serum Cu to Zn ratio (Cu/Zn) is associated with BC risk. Therefore, we evaluated serum Cu and Zn concentrations, and Cu/Zn in BC through meta-analysis.
Studies reporting serum Cu and/or Zn concentrations in BC patients and controls from 1991 to 2020 were identified from PubMed, CNKI, and Wanfang databases online. Based on a random effects model, summary standard mean differences (SMDs) and the corresponding 95 % confidence intervals (95 % CIs) were applied to compare the serum levels of Cu, Zn and Cu/Zn between BC patients and controls.
Thirty-six eligible studies involving 5747 female subjects were included. The present study illustrated that the BC patients had significantly higher serum Cu levels than healthy controls (HC) (SMD (95 % CI): 1.99(1.48, 2.49)) and patients with benign breast diseases (BD) (SMD (95 % CI): 0.99(0.38, 1.61)). However, Zn concentrations were statistically decreased in BC patients than HC (SMD (95 % CI): -1.20(-1.74, -0.66)) and BD (SMD (95 % CI): -1.13 (-1.73, -0.54)). Cu/Zn concentrations were remarkably increased in BC patients than HC (SMD (95 % CI): 2.75(1.79, 3.60)) and BD (SMD (95 % CI): 2.98(1.91, 4.05)) in some studies.
The results show that elevated serum levels of Cu and Cu/Zn, as well as decreased Zn might be associated with increased risk of breast cancer. These three parameters have the potential to distinguish breast cancer from benign breast diseases.
越来越多的研究探讨了血清铜（Cu）和/或锌（Zn）水平与乳腺癌（BC）之间的关系。然而，结果并不一致。目前尚不清楚血清铜锌比值（Cu/Zn）是否与 BC 风险相关。因此，我们通过荟萃分析评估了 BC 患者血清 Cu 和 Zn 浓度以及 Cu/Zn。
从 PubMed、CNKI 和万方数据库在线检索 1991 年至 2020 年期间报道的 BC 患者和对照者血清 Cu 和/或 Zn 浓度的研究。基于随机效应模型，应用汇总标准均数差（SMD）及其相应的 95%置信区间（95%CI）比较 BC 患者和对照者血清 Cu、Zn 和 Cu/Zn 水平。
共纳入 36 项符合条件的研究，涉及 5747 名女性。本研究表明，BC 患者的血清 Cu 水平明显高于健康对照者（HC）（SMD（95%CI）：1.99（1.48，2.49））和良性乳腺疾病（BD）患者（SMD（95%CI）：0.99（0.38，1.61））。然而，BC 患者的 Zn 浓度明显低于 HC（SMD（95%CI）：-1.20（-1.74，-0.66））和 BD（SMD（95%CI）：-1.13（-1.73，-0.54））。在某些研究中，BC 患者的 Cu/Zn 浓度明显高于 HC（SMD（95%CI）：2.75（1.79，3.60））和 BD（SMD（95%CI）：2.98（1.91，4.05））。
结果表明，血清 Cu 和 Cu/Zn 水平升高以及 Zn 水平降低可能与乳腺癌风险增加相关。这三个参数有可能将乳腺癌与良性乳腺疾病区分开来。
